Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;28(9):1187-1188.
doi: 10.1016/j.cmi.2022.05.026. Epub 2022 May 30.

Hospitalization as an outcome in ambulatory COVID-19 trials-not applicable in every setting

Isaac Núñez  1 , Sergio Iván Valdés-Ferrer  2 , Adrian Soto-Mota  3
Affiliations

Hospitalization as an outcome in ambulatory COVID-19 trials-not applicable in every setting

Isaac Núñez et al. Clin Microbiol Infect. 2022 Sep.
No abstract available

Keywords: COVID-19; Clinical trials; Molnupiravir; Nirmatrelvir; Remdesivir; SARS-CoV-2.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Pyridostigmine reduces mortality of patients with severe SARS-CoV-2 infection: A phase 2/3 randomized controlled trial.
    Fragoso-Saavedra S, Núñez I, Audelo-Cruz BM, Arias-Martínez S, Manzur-Sandoval D, Quintero-Villegas A, Benjamín García-González H, Carbajal-Morelos SL, PoncedeLeón-Rosales S, Gotés-Palazuelos J, Maza-Larrea JA, Rosales-de la Rosa JJ, Diaz-Rivera D, Luna-García E, Piten-Isidro E, Del Río-Estrada PM, Fragoso-Saavedra M, Caro-Vega Y, Batina I, Islas-Weinstein L, Iruegas-Nunez DA, Calva JJ, Belaunzarán-Zamudio PF, Sierra-Madero J, Crispín JC, Valdés-Ferrer SI. Fragoso-Saavedra S, et al. Mol Med. 2022 Nov 8;28(1):131. doi: 10.1186/s10020-022-00553-x. Mol Med. 2022. PMID: 36348276 Free PMC article. Clinical Trial.

References

    1. Humanitarian crises in a global pandemic. Lancet. 2020;396:447. doi: 10.1016/S0140-6736(20)31749-9. - DOI - PMC - PubMed
    1. Bhimraj A., Morgan R.L., Hirsch Shumaker A., Lavergne V., Baden L., Cheng V., et al. IDSA guidelines on the treatment and management of patients with COVID-19. 2022. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatmen... Available at: Accessed April 7, 2022.
    1. Hammond J., Leister-Tebbe H., Gardner A., Abreu P., Bao W., Wisemandle W., et al. Oral nirmatrelvir for high-risk, nonhospitalised adults with COVID-19. N Engl J Med. 2022;386:1397–1408. doi: 10.1056/NEJMoa2118542. - DOI - PMC - PubMed
    1. Jayk Bernal A., Gomes da Silva M.M., Musungaie D.B., Kovalchuk E., Gonzalez A., Reyes V.D., et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalised patients. N Engl J Med. 2022;386:509–520. doi: 10.1056/NEJMoa2116044. - DOI - PMC - PubMed
    1. Gottlieb R.L., Vaca C.E., Paredes R., Mera J., Webb B.J., Perez G., et al. Early remdesivir to prevent progression to severe COVID-19 in outpatients. N Engl J Med. 2022;386:305–315. doi: 10.1056/NEJMoa2116846. - DOI - PMC - PubMed